- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Toledo, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 143
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- Placebo, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more
- Conditions
- Kidney Transplant, Chronic Kidney Disease
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 19 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- empagliflozin, metformin, sulfonylurea
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ridgefield, Connecticut
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo to Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Orange, California • Torrance, California + 25 more
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo matching BI 690517, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
- Conditions
- PreDiabetes, Prediabetic State, Overweight and Obesity
- Interventions
- Empagliflozin, Multivitamin-Placebo
- Drug
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, Glimepiride, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
- Conditions
- Hepatic Glucose Metabolism
- Interventions
- Empagliflozin 25 MG, Control
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus Type 2
- Interventions
- Empagliflozin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, BI 10773 Placebo, BI 10773 / BI 1356, BI 10773 / BI 1356 Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 708 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 24
- States / cities
- Chino, California • Huntington Beach, California • San Diego, California + 20 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Patients
- Interventions
- Empagliflozin, Dorzagliatin
- Drug
- Lead sponsor
- Hua Medicine Limited
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- SGLT2, Metformin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
- Other
- Lead sponsor
- Foundation for Atlanta Veterans Education and Research, Inc.
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Type 2 Diabetes
- Interventions
- Empagliflozin 25 MG
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Heart Failure, Type II; Diabetes
- Interventions
- Empagliflozin, Placebo Oral Capsule
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Breast Cancer, Supportive Care in Cancer
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, empagliflozin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Tuscumbia, Alabama • Encino, California • La Mesa, California + 39 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Fresno, California
- Conditions
- Gout and Hyperuricemia
- Interventions
- Empagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,988 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Heart Transplant, Cardiovascular Disease, Kidney Disease
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Nashville, Tennessee • Houston, Texas + 3 more